Healthy Nevada Project Sharing Clinical Results with Consenting Participants
02 oct. 2018 08h00 HE
|
Renown Health
Reno, Nev., Oct. 02, 2018 (GLOBE NEWSWIRE) -- The Healthy Nevada Project led by Renown Institute for Health Innovation (Renown IHI) is announcing another landmark milestone – returning clinical...
Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
10 sept. 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer
10 avr. 2018 09h00 HE
|
ProLynx LLC
SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Prolynx LLC (San Francisco, CA) announced it received a Notice of Allowance for its DNA damage enhancer PLX038 (PEG~SN-38), currently in Phase 1...
Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO
06 juin 2016 10h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., June 06, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), reported today updated Phase 1 data from its DNA...
BRCA Gene Testing-Based Breast Cancer and Ovarian Cancer Keynote Speaker, Advocate, Advisor and 'Previvor' Launches 'BRCA Believer' Brand Inspired by Personal Experience
22 juil. 2014 14h23 HE
|
BRCA Believer
SAN DIEGO, CA--(Marketwired - July 22, 2014) - BRCA gene testing-based breast cancer and ovarian cancer keynote speaker, advocate, advisor and "previvor," Merilee Kern, today announced the launch of...
CONTEMPORARY OBSTETRICS AND GYNECOLOGY OF DAYTON ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
30 sept. 2013 10h34 HE
|
Genetic Technologies Group
DAYTON, Ohio, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Contemporary Obstetrics & Gynecology, part of the Providence Medical Group, today announced the availability of the BREVAGen™ predictive risk...
PEARL W. YEE, M.D. INC. OF SAN FRANCISCO ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
16 sept. 2013 10h08 HE
|
Genetic Technologies Group
SAN FRANCISCO, Sept. 16, 2013 (GLOBE NEWSWIRE) -- Pearl Yee, MD, FACOG and clinical professor at the University of California, San Francisco, is pleased to announce that her private practice, Pearl W....
OB/GYN ASSOCIATES IN LEWISBURG, PA ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST
26 août 2013 13h06 HE
|
Genetic Technologies Group
SUNBURY, PA., Aug. 26, 2013 (GLOBE NEWSWIRE) -- Russell Stankiewicz, MD, FACOG, CCD, NMCP, is pleased to announce that OB/GYN Associates of Lewisburg, P.C. in Lewisburg, PA is now offering the...
THE HEWITT CENTER FOR BREAST WELLNESS AT GRIFFIN HOSPITAL IN DERBY, CT LAUNCHES HIGH-RISK PROGRAM INCLUDING STATE-OF-THE-ART BREAST CANCER SCREENING OPTIONS
24 juin 2013 12h16 HE
|
Genetic Technologies Group
DERBY, Conn., June 24, 2013 (GLOBE NEWSWIRE) -- Denise Barajas, MD, medical director at The Hewitt Center for Breast Wellness in Derby, CT, has launched a high-risk breast cancer program that includes...
Atossa Genetics to Sponsor Screenings of Decoding Annie Parker at the Seattle International Film Festival on June 6 and 8, 2013
21 mai 2013 08h30 HE
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - May 21, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is sponsoring two screenings of the new film Decoding Annie Parker at the Seattle...